New Alzheimer’s Drugs Spark Hope for Patients and Cost Concerns for Medicare
(By Juliette Cubanski and Tricia Neuman for Kaiser Family Foundation published May 18, 2023) The FDA’s accelerated approval of Aduhelm
Read More
FDA
Eli Lilly says an experimental drug slows Alzheimer’s worsening
(Source -The Associated Press published May 4, 2023 by NPR) WASHINGTON — Eli Lilly and Co. said Wednesday its experimental
Read More26 state attorneys general urge Medicare to cover Alzheimer’s treatments
(By Rylee Wilson for Becker’s Hospital Review) Twenty-six state attorneys general are asking Medicare to cover monoclonal antibody treatments for
Read MoreAbbott glucose monitor readers could catch fire, FDA warns in recall notice
(By Lizzy Lawrence for STAT) Health care giant Abbott issued a warning impacting four million readers for glucose monitors after
Read MoreFDA has new leverage over companies looking for a quicker drug approval
(By Sydney Lupkin for NPR) The huge spending bill that became law last December also included fixes to a problem
Read MoreCMS STATEMENT: Response to Alzheimer’s Association’s Request to Reconsider the Final National Coverage Determination
(Source – www.cms.gov) Alzheimer’s disease is a devastating illness that affects millions of Americans and their families. The Centers for
Read MoreA Bitter Battle Over the ‘Orphan Drug’ Program Leaves Patients’ Pocketbooks at Risk
(By Sarah Jane Tribble for Kaiser Health News) A prescription drug that helps Lore Wilkinson walk and talk despite a
Read MoreAbbVie’s blockbuster drug Humira finally loses its 20-year, $200 billion monopoly
(Leslie Walker and Dan Gorenstein for NPR) After 20 years and $200 billion in revenue, Humira — an injectable treatment
Read MoreAn FDA committee votes to roll out a new COVID vaccination strategy
(By Scott Hensley for NPR) A committee of advisers to the Food and Drug Administration voted unanimously on a proposal
Read MoreA dangerous loophole for drug ads needs to be closed
(By John P. Moore and G. Caleb Alexander for STAT) A loophole in prescription drug regulation exposes American consumers to
Read More